Intra-Cellular Therapies’ Post

The TIDE trial, led by Professor Michael Berk and Professor Jee Hyun Kim, aims to understand if trimetazidine can help to reduce depressive symptoms in people with bipolar disorder. 'They are hopeful that trimetazidine will help treatment-resistant people with bipolar depression by directly targeting a different biological mechanism of depression compared to existing medications.' Read about the TIDE trial: https://deakin.au/4cnMw9s

#Depression is a common disease worldwide. According to WHO estimates, a total of 350 million patients worldwide suffer from depression, making it the fourth largest disease in the world and growing rapidly. Conventional depression is usually treated with medication and psychotherapy at the same time, but the efficacy is not satisfactory. Repetitive transcranial magnetic stimulation (#rTMS) is a commonly used clinical method to treat major depressive disorder (#MDD), and a large number of clinical studies have proven its effectiveness. A significant antidepressant effect can be achieved by 10Hz rTMS stimulation of the patient's dorsolateral cortex (DLPFC). Welcome to visit us at www.yingchitech.com #TMS #tmstreatment #transcranialmagneticstimulation

Rule #1 of neurotransmission - The brain’s response to a drug is always to facilitate the OPPOSITE state; therefore the only way for any regularly user of a drug to feel normal is to take the drug. Getting high, if it occurs at all, is increasingly short-lived, and so the purpose of using is to stave of withdrawal.    Rule #2 of neurotransmission - Any time you give a drug to increase the amount of a neurotransmitter, the synapse will remove receptors for that neurotransmitter, effectively making itself less sensitive to that drug. The opposite is true too.    Rule# 3 of neurotransmission - Unfortunately, the most powerful drugs tend to have the most severe and dangerous side effects. Because of this we can't always use the “big guns” right off the bat. It's best to attempt to treat with the least powerful option that will still produce good results.    I go into more depth on specific neurotransmitters and more in an update to my mental disorders crash course coming soon!!    My Basics of Neurotransmitters lesson is all about understanding the essentials of the primary neurotransmitters involved in the medications we prescribe and the disorders we treat.    Sign up for my mailing list to be notified when these new additions to my course are released as well as free weekly clinical pearls of practice ➡️https://lnkd.in/g2aw8d5J

This double-blind, parallel-group, randomized trial compared escitalopram and COMP360 psilocybin for treating major depressive disorder.,Psychedelic Insights | Find everything from psychedelic research to implementation | Interconnected Database | Psychedelic Reports | Timely Articles

Very few cases of hereditary hemochromatosis are linked with movement disorders. Discover how this condition can lead to excessive iron buildup in the brain, and what that could mean for diagnosing movement disorders: https://hubs.la/Q02zYRjQ0 #Hemochromatosis #MovementDisorders #IronDeposition

Major depressive disorder affects 280 million people globally and treatment decisions currently rely on a process of educated guessing. At Circular Genomics, we are pioneering a biomarker-based approach that aims to improve on the standard of care. #MindLight is an antidepressant response test that assists in predicting whether a patient will respond to #SSRI antidepressant treatment with the goal of helping patients get to the right treatment faster, avoiding prolonged periods of symptom persistence. Learn more at https://hubs.la/Q02QY0Vb0 #Depression #MajorDepressiveDisorder #AntidepressantTreatment #CircRNA

TMS Therapy: A Non-Invasive Breakthrough! Did you know that Transcranial Magnetic Stimulation (TMS) offers a medication-free alternative for treating depression? With a success rate of over 70%, it's changing lives without invasive procedures or more daily pills. #TMS #MentalHealth #BreakTheStigma"

Entirely new therapy for schizophrenia after 35 years just approved by FDA!! 🧠 KarXT’s Mechanism: Combining xanomeline and trospium, KarXT targets muscarinic receptors to reduce schizophrenia symptoms without affecting dopamine pathways, aiming to avoid typical antipsychotic side effects. #Schizophrenia #MuscarinicAgonist 💊 Efficacy in Trials: KarXT has shown a significant reduction in both positive and negative symptoms of schizophrenia, bringing a new approach to treatment after decades of dopamine-targeted therapies. #FDAApproval #MentalHealth ⚠️ Safety Considerations: Cardiovascular side effects were noted, but overall efficacy remains good. #DrugSafety Excellent news!! Source: https://lnkd.in/gS5__gXq

Parkinson’s Disease - do you know the signs to look out for? Parkinson’s is a degenerative neurological disorder that affects movement but are you aware of the symptoms to look out for in your loved ones? The indicators will come on gradually and include: ❗ Tremors or shaking ❗ Changes in speech ❗ Difficulty with balance ❗ Cognitive changes There are several treatment options for Parkinson’s in the elderly, including speech and physical therapy. Read our advice article for more symptoms and treatments to be aware of. https://lnkd.in/ewZvvB8h

Dysphagia (Difficulty Swallowing) Dysphagia or difficulty swallowing is a symptom of many different medical conditions. These conditions include nervous system and brain disorders, muscle disorders and physical blockages in your throat. Treatment for swallowing issues may include medications, changes to your eating habits and, sometimes, procedures. What causes dysphagia? Any disorder, disease or condition that impacts the muscles or nerves that help you swallow can cause dysphagia. Nervous system and brain disorders Conditions and injuries affecting your brain and nervous system (the network of nerves that controls muscles and organs) that cause dysphagia include: #RaiseAgainstAutism #PinnacleSaysItAll #PinnacleBloomsNetwork #1AutismTherapyCentresNetwork